Prospecto: information for the patient
Ofev 100mg soft capsules
nintedanib
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
1.What Ofev is and for what it is used
2.What you need to know before starting to take Ofev
3.How to take Ofev
4.Possible adverse effects
5.Storage of Ofev
6. Contents of the package and additional information
Ofev contains the active ingredient nintedanib, a medication that belongs to the class of tyrosine kinase inhibitors,and is used to treat the following diseases:
Idiopathic Pulmonary Fibrosis (IPF) in adults
IPF is a disease that causes thickening, hardening, and scarring of the tissue in your lungs over time. As a result, scarring reduces the ability to transfer oxygen from the lungs to the bloodstream, making it difficult to breathe deeply. Ofev helps to reduce the appearance of further scarring and hardening of the lungs.
Other chronic progressive fibrosing interstitial lung diseases (cP-ILDs) in adults
In addition to IPF, there are other diseases in which the tissue in your lungs presents thickening, hardening, and scarring over time (pulmonary fibrosis) and continues to worsen (progressive phenotype). Examples of these diseases include hypersensitivity pneumonitis, autoimmune interstitial lung diseases (such as interstitial lung disease associated with rheumatoid arthritis), idiopathic interstitial pneumonia, idiopathic interstitial pneumonia not classifiable, and other interstitial lung diseases. Ofev helps to reduce the appearance of further scarring and hardening of the lungs.
Chronic progressive fibrosing interstitial lung diseases (cP-ILDs) in children and adolescents aged 6 to 17 years
Fibrosis of the lungs can occur in patients with childhood interstitial lung disease. In this case, the lung tissue of children and adolescents presents thickening, hardening, and scarring over time.Ofev helps to reduce the appearance of further scarring and hardening of the lungs.
Interstitial lung disease associated with systemic sclerosis (ILD-SSc)in adults, adolescents, and children aged 6 years and older
Systemic sclerosis (SSc), also known as scleroderma (and systemic sclerosis in children and adolescents), is a rare chronic autoimmune disease that affects the connective tissue in many parts of the body. SSc causes fibrosis (scarring and hardening) of the skin and other internal organs, such as the lungs. When the lungs are affected by fibrosis, it is called interstitial lung disease (ILD) and, therefore, the disease is called ILD-SSc. Fibrosis in the lungs reduces the ability to transfer oxygen to the bloodstream and reduces the ability to breathe. Ofev helps to reduce the appearance of further scarring and hardening of the lungs.
Do not take Ofev
Warnings and precautions
Consult your doctor or pharmacist before starting to take Ofev
Based on this information, your doctor may perform some blood tests, for example, to check your liver function. Your doctor will discuss the results of these tests with you to decide if you can take Ofev.
Inform your doctor immediately while taking this medication
Children and adolescents
Children under 6 years old should not take Ofev.
Other medications and Ofev
Inform your doctor or pharmacist if you are taking, have taken recentlyormay have to take any other medication, including herbal remedies and over-the-counter medications.
Ofev may interact with other medications. The following medications may
increase the levels of nintedanib in the blood and, therefore, increase the risk of adverse effects (see section4, “Possible side effects”):
-a medication used to treat fungal infections (ketoconazole)
-a medication used to treat bacterial infections (erythromycin)
-a medication that affects your immune system (ciclosporin)
The following medications are examples that may decrease the levels of nintedanib in the blood and, therefore, reduce the effectiveness of Ofev:
-an antibiotic used to treat tuberculosis (rifampicin)
-medications used to treat seizures (carbamazepine, phenytoin)
-a herbal remedy used to treat depression (St. John's Wort)
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
Do not take this medication during pregnancy, as it may harm the fetus and cause congenital defects.
You should have a pregnancy test to ensure you are not pregnant before starting treatment with Ofev. Consult your doctor.
Contraception
Breastfeeding
Do not breastfeed your baby while taking Ofev, as it may harm the infant.
Driving and operating machinery
Ofev has little effect on the ability to drive and use machines. Do not drive or use machines if you feel dizzy.
Ofev contains soy lecithin
If you are allergic to soy or peanuts, do not take this medication (see section2, “Do not take Ofev”).
Follow exactly the administration instructions of this medication indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Take the capsulestwice a daywith a 12-hour difference and approximately at the same time of day; for example, one capsule in the morning and one capsule at night. This way, you will ensure that a constant level of nintedanib is maintained in your blood. Swallow the capsules whole with water, without crushing them. It is recommended to take the capsules with food, that is, during meals or immediately before or after them.Do not open or break the capsule (see section5, “Conservation of Ofev”).
To make it easier to swallow the capsules, you can take themwith a small amount (one teaspoon) of a soft, cold or room-temperature food, such as apple sauce or chocolate pudding. Swallow the capsules immediately and do not crush them to ensure they remain intact.
Adults
The recommended dose is one capsule of 100mg twice a day (a total of 200mg per day).
Do not take more than the recommended dose of two Ofev 100mg capsules per day.
If you do not tolerate the recommended dose of two Ofev 100mg capsules per day (see possible side effects in section4), your doctor may recommend that you stop taking this medication. Do not reduce the dose or interrupt treatment on your own without consulting your doctor first.
Use in children and adolescents
The recommended dose depends on the patient's weight.
Inform your doctor if, at any time during treatment, the patient's weight is less than 13.5kg.
Inform your doctor if you have liver problems.
Your doctor will determine the correct dose. Your doctor may adjust the dose during the course of treatment.
If you do not tolerate the recommended daily dose of Ofev capsules (see possible side effects in section4), your doctor may reduce the daily dose of Ofev.
Do not reduce the dose or interrupt treatment on your own without consulting your doctor first.
Dosage based on weight for Ofev capsules in children and adolescents:
Weight interval andnin kilograms (kg) | Ofev dose in milligrams (mg) |
13.5‑22.9kg | 50mg (two 25mg capsules) twice a day |
23.0‑33.4kg | 75mg (three 25mg capsules) twice a day |
33.5‑57.4kg | 100mg (one 100mg capsule or four 25mg capsules) twice a day |
57.5kg or more | 150mg (one 150mg capsule or six 25mg capsules) twice a day |
If you take more Ofev than you should
Contact your doctor or pharmacist immediately.
If you forgot to take Ofev
Do not take two capsules together if you forgot to take your previous dose. You should take your next Ofev dose according to the established schedule at the next recommended hour and as indicated by your doctor or pharmacist.
If you interrupt treatment with Ofev
Do not stop taking Ofev without consulting your doctor first. It is essential to take this medication every day while your doctor prescribes it.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
You should pay special attention if you experience the following side effects during treatment with Ofev:
Diarrea(very common, may affect more than 1 in 10 people):
Diarhea can cause dehydration: a loss of important body fluids and salts (electrolytes, such as sodium or potassium). If you experience the first symptoms of diarrhea, drink plenty of liquid and consult your doctor immediately. Start an appropriate antidiarrheal treatment as soon as possible, for example, by taking loperamide.
The following side effects have also been observed during treatment with this medicine.
Consult your doctor if you experience any type of side effect.
Idiopathic Pulmonary Fibrosis (IPF)
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
Other chronic fibrosing interstitial lung diseases (cEIP) with a progressive phenotype
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
Interstitial lung diseases (cEIP) associated with systemic sclerosis (cEIP-SSc)
Very common side effects (may affect more than 1 in 10 people)
Common side effects (may affect up to 1 in 10 people)
Uncommon side effects (may affect up to 1 in 100 people)
Frequency not known (cannot be estimated from available data)
Interstitial lung diseases (cEIP) in children and adolescents
The side effects in children and adolescents were similar to the side effects in adult patients.
Inform your doctor if you experience any type of side effect.
Reporting of side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national notification system included in theAppendixV. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the blister pack. The expiration date is the last day of the month indicated.
Do not store at a temperature above 25°C.
Store in the original packaging to protect it from moisture.
Do not use this medication if you observe that the blister pack containing the capsules is open or that a capsule is broken.
If you come into contact with the contents of the capsule, wash your hands immediately with plenty of water (see section3, “How to take Ofev”).
Medicines should not be disposed of through the drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Composition of Ofev
-The active ingredient is nintedanib. Each capsule contains 100mg of nintedanib (as esilate).
-The other components are:
Caplet content:medium-chain triglycerides, hard fat, soy lecithin(E322) (see section 2, “Do not take Ofev”)
Outer capsule coating:gelatin, glycerol (85%), titanium dioxide (E171), iron oxide red (E172), iron oxide yellow (E172)
Appearance of the product and contents of the package
Ofev 100mg capsules are soft gelatin oval-shaped, opaque, and yellowish-orange(approximately 16×6mm), marked on one side with the Boehringer Ingelheim logo and the number“100”.
There are two package sizes of Ofev 100mg capsules:
-30×1capsules in pre-cut, unit-dose blisters of aluminum/aluminum
-60×1capsules in pre-cut, unit-dose blisters of aluminum/aluminum
Only some package sizes may be marketed.
Marketing Authorization Holder
Boehringer Ingelheim International GmbH
Binger Strasse173
55216Ingelheim am Rhein
Germany
Responsible for manufacturing
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse173
55216Ingelheim am Rhein
Germany
Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
For more information about this medicine, please contact the local representative of the marketing authorization holder:
België/Belgique/Belgien Boehringer Ingelheim SComm Tél/Tel: +32 2 77333 11 | Lietuva Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel: +3705 2595942 |
Tel: +359 2 958 79 98 | Luxembourg/Luxemburg Boehringer Ingelheim SComm Tél/Tel: +32 2 773 33 11 |
Ceská republika Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Magyarország Boehringer Ingelheim RCV GmbH & Co KG Magyarországi Fióktelepe Tel: +36 1 299 89 00 |
Danmark Boehringer Ingelheim Danmark A/S Tlf.: +45 39 15 88 88 | Malta BoehringerIngelheim Ireland Ltd. Tel: +353 1 295 9620 |
Deutschland Boehringer Ingelheim Pharma GmbH & Co.KG Tel: +49 (0) 800 77 90 900 | Nederland Boehringer Ingelheim B.V. Tel: +31 (0) 800 22 55 889 |
Eesti Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal Tel: +372 612 8000 | Norge Boehringer Ingelheim Danmark Norwegian branch Tlf: +47 66 76 13 00 |
Ελλ?δα Boehringer IngelheimΕλλ?ςΜονοπρ?σωπηA.E. Tηλ: +30 2 10 89 06 300 | Österreich Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
España Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Polska Boehringer Ingelheim Sp. z o.o. Tel: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal,Lda. Tel: +351 21 313 53 00 |
Hrvatska Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | România Boehringer Ingelheim RCV GmbH & Co KG Viena–Sucursala Bucuresti Tel: +40 21 302 2800 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana Tel: +386 1 586 40 00 |
Ísland Vistor ehf. Sími: +354 535 7000 | Slovenská republika Boehringer Ingelheim RCV GmbH & Co KG organizacná zložka Tel: +421 2 5810 1211 |
Italia Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102 800 |
Κ?προς Boehringer IngelheimΕλλ?ς Μονοπρ?σωπηA.E. Tηλ: +30 2 10 89 06 300 | Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvija Boehringer Ingelheim RCV GmbH & Co KG Latvijas filiale Tel: +371 67 240 011 |
Last update of this leaflet:
The detailed information on this medicine is available on the website of the European Medicines Agency:https://www.ema.europa.eu.
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.